Search

AT THE EAU CONGRESS ISTANBUL, TURKEY--The investigational interleukin-17A inhibitor secukinumab was the talk of Europe's premier dermatology conference as a result of a series of world-premiere presentations of not one, [...]

FROM THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY SAN DIEGO - An investigational first-in-class drug not only improved plaque psoriasis but reduced atherosclerotic inflammation in major vessels, a [...]

FROM THE NEW ENGLAND JOURNAL OF MEDICINE Two monoclonal antibodies 1 targeting interleukin-17 proved effective and safe for moderate to severe plaque psoriasis, according to the results of two phase [...]

BOSTON -- Data suggesting that pregnant women with psoriasis have poorer outcomes than those without it highlight the need for more research to determine whether the outcome discrepancies are a [...]

MONTREAL -- Mortality rates are significantly increased in patients with severe psoriasis compared with the general population, according to two new studies. But the studies have conflicting results regarding cause [...]

SAN ANTONIO -- Long-term, continuous use of ustekinumab for maintenance therapy in patients with moderate to severe plaque psoriasis is efficacious and generally well tolerated, according to phase III study [...]

Psoriasis appears to be an independent risk factor for myocardial infarction, conferring the same magnitude of risk as other major cardiac risk factors, according to Dr. Joel M. Gelfand of [...]

NEW YORK -- There is mounting evidence that stress and the way in which patients with psoriasis view themselves or perceive themselves to be seen affects the way that they [...]

KOHALA COAST, HAWAII -- New data suggest that etanercept can be given intermittently like other psoriasis treatments, according to a poster that Alice B. Gottlieb, M.D., presented at a conference [...]

VIENNA -- The time has come to abandon the traditional stepwise therapeutic approach to psoriasis in light of the biologic agents' well-documented advantages over older systemic therapies, according to a [...]

Many patients who suffer an attack of generalized pustular psoriasis appear to have liver abnormalities, a finding that was previously noted only in isolated cases. During 1995-2001, Dr. Manuelle Viguier [...]

Watch out, psoriasis, there's a "new" treatment in town--officially. The Food and Drug Administration has approved the biologic agent etanercept (Enbrel) for the treatment of chronic moderate to severe plaque [...]

PROVIDENCE, R.I. -- The efficacy and safety of efalizumab do not appear to deteriorate during the long-term treatment of patients with moderate to severe chronic plaque psoriasis, Dr. Alice B. [...]

AMELIA ISLAND, FLA. -- Several promising new drugs for psoriasis patients are in development or en route to the United States, adding to the existing arsenal of nonbiologic treatment options, [...]

WASHINGTON -- Calcitriol ointment was a safe and effective treatment for chronic plaque psoriasis in a pair of controlled, 8-week studies with a total enrollment of more than 800 patients. [...]

NEW YORK -- Collectively hailed as the biggest breakthrough for psoriasis therapy in decades, infliximab, etanercept, alefacept, and the other "targeted biologics" seem poised to revolutionize how dermatologists treat moderate [...]